Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (1002)	5/19/1998 8:34:00 PM
From: seminole	Read Replies (1) \| Respond to of 1826

Mr Bear I dislike this report on the Phase I trials. There is no dose information and no qualitative or quantitative information on the tumors. The title of the presentation says clinical data is being presented but I don't see any data. Perhaps, the problem is with the person reporting but this announcement seems weak. Last year Blitzer said, "We own all the rights to one of the most exciting anti-cancer drugs in human clinical developement today". For this to be true, they should have seen tumor regression in humans. On April 16,1997, Blitzer reported, "Last week, we saw the first evidence of anti-tumor activity in humans with MGI 114 by a CT-scan showing shrinkage of a tumor in a patient enrolled in our Phase I study". Why not include the qualitative or quantitative information on tumor regression for the Am. Soc. of Clinical Oncology? Sure the purpose of Phase I trials is toxic dose but please don't hold back information on the tumors. Once again, hopefully this is a reporting problem. I trust the drug but don't understand this understated press release. richard

To: Russian Bear who wrote (1002)	5/19/1998 8:37:00 PM
From: bocaburgerman	Respond to of 1826

Russian Bear, If results are positive, watch out. Consider that the company is under followed by Wall Street. There are a lot of financial web sites still showing a single outdated hold status on MGI. It's outdated since the analyst stopped covering MGI. Consider that at the current price, the market cap of this stock is still 147 million. If Phase II results show positive and MGI can hold onto the U.S. market rights, we are all going to be quite wealthy. IF it doesn't, the Salagen profits, will still provide very decent growth for a company of this size. Psuedo news. Fun stuff. Winston